UK drug giant teams up with French rival for Covid-19 vaccine
GlaxoSmithKline hopes to have coronavirus treatment available next year
A leading British drug company is joining forces with a French rival to develop a coronavirus vaccine and manufacture hundreds of millions of doses.
GlaxoSmithKline is to team up with Sanofi on a treatment that they hope to test on humans during the second half of 2020 and make available a year later if regulators grant approval.
The Times says the tie-up is “significant” because it “raises the prospect that a Covid-19 treatment could be manufactured quickly on the large scale required to tackle the pandemic”.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
–––––––––––––––––––––––––––––––For a round-up of the most important stories from around the world - and a concise, refreshing and balanced take on the week’s news agenda - try The Week magazine. Start your trial subscription today –––––––––––––––––––––––––––––––
The chief executive of GSK, Emma Walmsley, said: “We’re committed to making any vaccine that’s developed through the collaboration affordable to the public.”
She said the company does not intend to profit from the intiative and plans to donate the therapy to the world’s poorest countries.
Sanofi is offering a Covid-19 antigen — the molecule that helps the body to produce antibodies — it is developing, while GSK brings to the table its adjuvant technology, which boosts an antigen’s potency and makes smaller doses more effective.
As the BBC reports, vaccines work by introducing a small amount of a virus or bacteria to the immune system. This means that when the body comes into contact with the illness for real, it recognises it as an “invader” and knows how to fight it.
Although the timescale of a Covid-19 vaccine only being available in the second half of next year seems painfully slow, most vaccines take a decade or more to get regulatory approval.
The World Health Organization said there are 70 separate Covid-19 vaccines in development. Among those scrambling to produce one is a team led by Sarah Gilbert, professor of vaccinology at Oxford University, who told The Times last week that she was “80% confident” that their treatment would work, possibly by September.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
How to find cheaper car insurance as premiums accelerate
The Explainer Car insurance costs are rising but there are ways to put the brakes on price rises
By Marc Shoffman, The Week UK Published
-
What to know when planning an awe-inspiring hike on the Inca Trail
The Week Recommends Peru's most famous trail leads to Machu Picchu
By Catherine Garcia, The Week US Published
-
Lead poisoning remains a threat
The Explainer The toxin is built into our lives
By Devika Rao, The Week US Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published
-
Long-term respiratory illness is here to stay
The Explainer Covid is not the only disease with a long version
By Devika Rao, The Week US Published
-
Covid inquiry: the most important questions for Boris Johnson
Talking Point Former PM has faced weeks of heavy criticism from former colleagues at the public hearing
By The Week Staff Published
-
China's pneumonia cases: should we be worried?
The Explainer Experts warn against pushing 'pandemic panic button' following outbreak of respiratory illness
By Keumars Afifi-Sabet, The Week UK Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published